Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis | Zendy

Devyani Deshpande | Zendy; Jotam G. Pasipanodya | Zendy; Stellah Mpagama | Zendy; Shashikant Srivastava | Zendy; Paula Bendet | Zendy; Thearith Koeuth | Zendy; Pooi S Lee | Zendy; Scott K. Heysell | Zendy; Tawanda Gumbo | Zendy

Open Access

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis

Author(s) -

Devyani Deshpande,

Jotam G. Pasipanodya,

Stellah Mpagama,

Shashikant Srivastava,

Paula Bendet,

Thearith Koeuth,

Pooi S Lee,

Scott K. Heysell,

Tawanda Gumbo

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy609

Subject(s) - ethionamide , ethambutol , medicine , tuberculosis , pharmacology , isoniazid , pharmacodynamics , mycobacterium tuberculosis , pharmacokinetics , pathology

Ethionamide is used to treat multidrug-resistant tuberculosis (MDR-TB). The antimicrobial pharmacokinetics/pharmacodynamics, the contribution of ethionamide to the multidrug regimen, and events that lead to acquired drug resistance (ADR) are unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research